Aratana Therapeutics, Inc. (PETX)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 3.30 / 6.77
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Small Biotechs Finally Join in Market Rebound

Small Biotechs Finally Join in Market Rebound

Exelixis Inc. and Aratana Therapeutics in particular surge after posting solid results Thursday.

3 Tiny Explosive Biotech Stocks for 2018

3 Tiny Explosive Biotech Stocks for 2018

Sector M&A activity is likely to pick up next year benefiting the space.

Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers

Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers

The Fremont, Calif.-based firm and Kyowa Hakko Kirin signed a license pact for Ardelyx's lead investigational product, tenapanor.

Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers

Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers

The South San Francisco, Calif.-based company said Oct. 16 its Phase 3 study of cabozantinib achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma.

3 Biotech Values in a Fully Valued Market

3 Biotech Values in a Fully Valued Market

Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise.

3 Biotech Values in a Fully Valued Market

3 Biotech Values in a Fully Valued Market

Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise ahead.

2 Animal Drugmakers Worth a Sniff

2 Animal Drugmakers Worth a Sniff

Aratana Therapeutics and Kindred Biosciences are promising drug developers in the pet space.

Non-FANG Stocks May Finally Get Some Love

Non-FANG Stocks May Finally Get Some Love

Tech meltdown provides an opportunity for rotation into undervalued sectors.

Liking the Look of Some of These Pullbacks

Liking the Look of Some of These Pullbacks

This corrective action has me feeling optimistic about some new opportunities.

Two Small Growth Stories

Two Small Growth Stories

An update on two small-caps that reported earnings.

Takeaways & Observations

I wanted to start by congratulating El Capitan for his 12th anniversary for Mad Money tonight. Like the Energizer Bunny, he keeps going and going...  HIgh yield gets junky -- despite protestations from Merrill's junk department! I have been warning ...

Shark Bites: Market Needs a Bounce in Its Step

Shark Bites: Market Needs a Bounce in Its Step

Biotechnology continues to be a bright spot.

3 Small Biotechs That Still Have Upside

3 Small Biotechs That Still Have Upside

Companies developing drugs for cancer, eye problems and pets -- offer untapped value.

Welcome to the Small-Cap Biotech Mailbag!

Welcome to the Small-Cap Biotech Mailbag!

We answer recent reader questions about three of the biotech stocks we regularly cover.

Scanning the Biotech Universe

Markets are slightly down in the early going. Gilead Science GILD is off about 9% on dismal revenue guidance for 2017 and price target downward revisions at various analyst firms. If 2017 projections do not light a fire under company to use mergers ...

My Takeaways and Observatons

"As to the markets, it trades like participants are sleeping off hangovers from partying hard during last night's Super Bowl thriller." -- "Is Another Lesson Soon to be Learned?"   With such little price action it seemed like a snore fest (see above...

Shark Bites: If You're Not in the Right Stocks, You're in Trouble

Shark Bites: If You're Not in the Right Stocks, You're in Trouble

Market is showing a lack of interest today.

Trading Action Has Improved, Here's What I Am Playing

Trading Action Has Improved, Here's What I Am Playing

Market players are sorting out the winners and losers, and that produces good opportunities if we keep on digging.

It's an Actual Pullback for a Change

It's an Actual Pullback for a Change

This morning the most notable aspect of the action is the complete failure to bounce so far.

So We Hit Dow 20K, Now What?

So We Hit Dow 20K, Now What?

Keep in mind that moves like this create underlying support.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Stock Picks Are Hard to Find as Small-Caps Struggle

Stock Picks Are Hard to Find as Small-Caps Struggle

With poor breadth and money managers hiding in large-caps, I am being cautious, right now.

3 Biotechs Screaming 'Takeover Target'

3 Biotechs Screaming 'Takeover Target'

M&A activity should perk up substantially in the small and mid-cap space this year.

Trying to Knock Out Some Individual Trades, but it Is not Easy

Trying to Knock Out Some Individual Trades, but it Is not Easy

If the indices take out yesterday's lows I'll be very bearish very quickly.

My Top 2017 Pick: Progenics Pharmaceuticals

My Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher this year.

Market Sees Rise in Performance Anxiety

Market Sees Rise in Performance Anxiety

I've got my eye on steel and biotechnology names to put cash to work.

Top 2017 Pick: Progenics Pharmaceuticals

Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher next year.

7 Low-Priced Stocks to Watch in 2017

7 Low-Priced Stocks to Watch in 2017

Good picks make it easier to produce good results, but they are just a starting point.